Healthcare & Life Sciences

Patent Application for Whitening Cosmetic Composition with Artemisinic Acid

The USPTO has published a patent application (US20260083657A1) for a whitening cosmetic composition containing artemisinic acid, nicotinamide, and/or glutathione. The application, filed by Yunnan Botanee Bio-Technology Group Co., Ltd., describes a formulation designed to inhibit melanin production and reduce skin irritation.

Cleansing composition with carnosine, magnesium, caffeine

The USPTO has published a new patent application (US20260083658A1) for a personal cleansing composition. The composition includes carnosine, magnesium salt, caffeine, and transdermal absorption enhancers, designed for use in products like shower gels and soaps.

Skincare Therapeutic Balm Preparation Method Patent Application

The USPTO has published a patent application (US20260083662A1) for a skincare and therapeutic balm preparation method. The application, filed by Fine Washed LLC, details a method combining Ethiopian black seed oil with Illinois sourced beef tallow.

USPTO Patent Application for Disease Treatment Method

The USPTO has published patent application US20260083666A1 for a method of treating diseases and ameliorating pain by administering a composition to the ear canal. The application was filed on April 10, 2025, and published on March 26, 2026.

Sulforaphane Supplement in Gummy Form Patent Application

The USPTO has published a patent application (US20260083667A1) for a sulforaphane supplement in gummy form. The application, filed by Sensory Scout LLC, describes a composition including sulforaphane, glucoraphanin, and myrosinase immobilized within a gummy matrix. This represents a new patent filing for a novel supplement formulation.

USPTO Patent for Implantable Biodegradable Drug Delivery Devices

The USPTO has published a patent application (US20260083665A1) for implantable and biodegradable drug delivery devices. The invention aims to deliver active pharmaceutical ingredients directly to target tissue sites using layered biodegradable polymers.

Patent Application: Intrathecal T regulatory cells for Multiple Sclerosis Treatment

The USPTO has published a patent application (US20260083664A1) for a medicinal product involving intrathecal administration of T regulatory cells for treating multiple sclerosis. The application was filed on December 3, 2025, by inventors Piotr Trzonkowski and Kamil Chwojnicki.

Botanical Compositions and Methods of Production and Use

The USPTO has published a new patent application, US20260083663A1, detailing botanical compositions with plant extracts and their preparation methods. The application was filed on September 11, 2023, and is scheduled for publication on March 26, 2026. This represents a new disclosure of potential intellectual property in the pharmaceutical sector.

Patent Application for Genome Editing Compositions and Methods

The USPTO has published a new patent application (US20260083860A1) for genome editing compositions and methods. The application, filed on August 19, 2025, by inventors Oscar ALVAREZ, Ming-Yue LEE, and Blair B. MADISON, details methods and compositions for functional genetic modifications.

CRISPR Methods Targeting CD70 Expression for Engineered Cells

The USPTO has published a patent application (US20260083861A1) filed by Editas Medicine, Inc. The application describes CRISPR-related systems and methods for targeting the CD70 gene expression in engineered cells, particularly T cells, for potential therapeutic applications.

Patent Application: Treating Brain Diseases with rAAV Particles

The USPTO has published a new patent application (US20260083862A1) from the University of Iowa Research Foundation detailing methods for treating brain diseases using rAAV particles administered via the cisterna magna. The application was filed on May 19, 2025.

Oil-in-water emulsions for topical administration with hyaluronan

The USPTO has published a patent application (US20260083673A1) for oil-in-water emulsions containing hyaluronan for topical administration. The application details formulations for treating various dermatological conditions, including inflammatory dermatoses, acne, alopecia, and fibrosing pathologies.

Patent Application for Stabilized Galectin-9 Protein Pharmaceutical Formulation

The USPTO has published a patent application (US20260083671A1) for a stabilized pharmaceutical formulation containing a recombinant stabilized galectin-9 protein. The application details a formulation designed for improved stability through the combination of a buffer and a stabilizer.

NALIRFAL Trademark Application Published for Opposition

The USPTO has published the trademark application for NALIRFAL, which includes a variety of dietary and nutritional supplements. The application was published for opposition on March 25, 2026, with a filing date of March 24, 2026. This publication initiates a period during which other parties may oppose the trademark registration.

PRÜF Intent to Use Trademark Application Filed

The USPTO has received an intent-to-use trademark application for the mark 'PRÜF' filed on March 25, 2026. The application, filed on September 24, 2025, pertains to dietary and nutritional supplements.

HIVANO Intent to Use Trademark Application

The USPTO has received an intent-to-use trademark application (TM99722503) for the mark 'HIVANO'. The application covers a wide range of goods including athletic apparel, footwear, and various supplements (probiotic, homeopathic, mineral, herbal, vitamin, calcium, food, dietary, nutritional, and natural herbal). It also includes services related to nutrition counseling and information provision.

POWERSTOVE Trademark Application Published for Opposition

The USPTO has published the trademark application for 'POWERSTOVE' for opposition. The application covers a range of products including personal sexual lubricants, dietary supplements, pet supplements, vitamins, and other health-related items. The publication date for opposition is March 25, 2026.

TEMIMAR trademark application published for opposition

The USPTO has published the trademark application for 'TEMIMAR' for opposition. The application covers natural herbal supplements, vitamin supplements, and other health-related food products. The publication date is March 25, 2026.

7 LIFE Trademark Application Published for Opposition

The USPTO has published the trademark application for '7 LIFE' for opposition. The application, filed on March 24, 2026, is for dietary supplements. The publication date is March 25, 2026, initiating a period for potential opposition.

CHIGGER OFF Intent to Use Trademark Application

The USPTO has received an Intent to Use trademark application for 'CHIGGER OFF' for topical dermatological preparations. The application was filed on March 24, 2026, with an effective date of March 25, 2026. This filing pertains to a new product intended to treat insect bites and stings.

FIBRIBION Trademark Publication

The USPTO has published the FIBRIBION trademark application for opposition. The application covers nutritional supplements, probiotic compositions, and dietary supplements. The publication date is March 25, 2026.

JUVONA intent to use trademark application filed

The USPTO has received an intent-to-use trademark application for the mark 'JUVONA' filed on March 25, 2026. The application covers goods including dietary supplements, nutritional supplements, and nutraceuticals for human consumption.

HEALTHYBLOOD Trademark Published for Opposition

The USPTO has published the HEALTHYBLOOD trademark application for opposition. The application covers various types of nutritional and dietary supplements. The publication date was March 25, 2026, with a filing date of March 24, 2026.

VERIXA trademark application published for opposition

The USPTO has published the trademark application for 'VERIXA' for opposition. The application covers insect repellents, insecticides, and rodenticides. The filing date was March 24, 2026, and the publication date is March 25, 2026.

BIOTHRIVE Trademark Application - Intent to Use

The USPTO has received an intent-to-use trademark application for the mark 'BIOTHRIVE' filed on March 24, 2026. The application covers health food supplements, dietary supplements, herbal supplements, and vitamin and mineral supplements.

ELTHYSIA Trademark Application - Intent to Use

The USPTO has recorded an intent-to-use trademark application for the mark 'ELTHYSIA'. The application covers a wide range of products including vitamins, dietary supplements, and pet supplements. The filing date for this application was March 24, 2026.

ASTANEURO Trademark Application Published for Opposition

The USPTO has published the trademark application for ASTANEURO, filed on March 24, 2026, for opposition. This notice indicates the application is now open for challenges from other parties before it can be registered.

NOURISHA intent to use trademark application details

The USPTO has recorded an intent-to-use trademark application (TM99692572) for the mark 'NOURISHA'. The application covers a range of pharmaceutical and food-related products, including milk-based nutritional supplements and dietetic preparations. The filing date for this application was March 10, 2026.

KYNTO Trademark Published for Opposition

The USPTO has published the KYNTO trademark application for opposition, related to dietary supplements. The application was filed on March 24, 2026, and the publication date for opposition is March 25, 2026. This marks a step in the trademark registration process.

JOINT AND JOINT Trademark Published for Opposition

The USPTO has published the trademark application for 'JOINT AND JOINT' for health food supplements, initiating a 30-day opposition period. The application was filed on March 24, 2026, and published for opposition on March 25, 2026.

Vitaminloft Intent to Use Trademark Application

The USPTO has published details for an intent-to-use trademark application for the mark 'VITAMINLOFT'. The application covers a wide range of pharmaceutical and health-related products, including supplements, vitamins, topical preparations, and disinfectants.

VALISSE intent to use trademark application filed

The United States Patent and Trademark Office (USPTO) has received an intent-to-use trademark application for the mark 'VALISSE'. The application, filed on March 24, 2026, covers health food supplements, dietary supplements, herbal supplements, and vitamin and mineral supplements.

KARENZA Trademark Intent to Use Application

The USPTO has received an intent-to-use trademark application for the mark 'KARENZA' for use with dietary supplements. The application was filed on March 24, 2026, and is designated for Class 005.

Shielded Bag for Radioactive Medicaments Delivery System

The USPTO has published a new patent application (US20260083981A1) for a shielded bag designed for delivering radioactive medicaments. The application, filed by Christopher James Franzese and Martin Michael Coyne, III, details a multi-layered container for storing and transporting radiopharmaceuticals.

Patent Application for Patient Health Monitoring Device

The USPTO has published a new patent application (US20260083959A1) for a patient health monitoring device and method. The application details a device that processes pressure signals to monitor a patient's health state. This is a routine publication of a new patent application.

Medical Fluid Pump Patent Application

The USPTO has published a new patent application (US20260083958A1) for a fluid pump device, particularly for medical applications. The application was filed on December 2, 2025, and published on March 26, 2026.

Medical Device Patent: Circulatory Support System with Diaphragm Pump

The USPTO has published a new patent application (US20260083957A1) for a circulatory support system with a diaphragm pump, assigned to Boston Scientific Scimed, Inc. The application details a percutaneous circulatory support device system designed to pump blood.

Pumping Device Patent Application Published

The USPTO published a patent application for a new pumping device designed for feeding liquid to patients. The application, filed on September 25, 2024, describes a disposable pumping cartridge and a reusable drive unit, aiming for economical assembly and use.

Implantable Reservoir for Iontophoresis Drug Delivery System

The USPTO has published a new patent application (US20260083966A1) for an implantable reservoir designed for iontophoresis drug delivery systems. The application details a reservoir for local drug delivery through internal or external body tissue, potentially including chemotherapeutic agents or ribonucleic acid molecules.

Mechanical Circulatory Support System Patent Application

The USPTO has published a new patent application (US20260083956A1) for a mechanical circulatory support system with a repositioning sheath, assigned to Boston Scientific Scimed, Inc. The application details a medical device system designed to pump blood from a patient's heart ventricle to the vasculature.

USPTO Patent Application for Blood Pump Outflow Window Markings

The USPTO has published a new patent application (US20260083955A1) filed by Boston Scientific Scimed, Inc. The application describes percutaneous blood pump outflow window markings for a circulatory support device. This is a routine publication of a patent application.

US Patent Application for Antigen Production Methods

The USPTO has published a new patent application (US20260085100A1) from The Wistar Institute of Anatomy and Biology detailing methods for manufacturing individualized vaccines. The application focuses on nucleic acid molecules encoding neoantigens specific to tumor antigens for use in subject immunization.

Novel Platelet Derived Growth Factor Peptide Mimetic for Cardiac Repair

The USPTO has published a patent application (US20260085101A1) for a novel platelet-derived growth factor peptide mimetic designed for cardiac repair, particularly post-infarction. The application details specific compounds, their preparation, and methods of use.

Patent Application for Synthetic Promoters and Circuits in Cancer Cells

The USPTO has published a patent application (US20260085102A1) for nucleic acid molecules designed to specifically express sequences of interest in cancer cells. The application details synthetic promoters and circuits for use in cancer treatment.

Long-acting insulin compound for treating diabetes

The USPTO has published a patent application (US20260085103A1) for a long-acting insulin compound designed for treating diabetes. The application details the compound's use in pharmaceutical compositions for conditions including type-I, type-II, and gestational diabetes.

Patent Application for Tenosynovial Giant Cell Tumor Treatment

The USPTO has published a patent application (US20260085124A1) detailing compositions and methods for treating tenosynovial giant cell tumor using intra-articular delivery of anti-CSF1R antibodies. The application, filed by Kirk William Johnson, focuses on sustained drug exposure within joints.

Patent Application: Anti-FGFR2 Antibodies with Chemotherapy for Cancer Treatment

The USPTO has published patent application US20260085123A1, filed by Five Prime Therapeutics, Inc. The application details the use of anti-FGFR2 antibodies in combination with mFOLFOX6 chemotherapy for treating certain cancers.

Patent Application: Antibodies Binding Human 4Ig-B7H3

The USPTO has published a new patent application (US20260085122A1) filed by BeOne Medicines I GmbH. The application relates to antibodies or antigen-binding fragments thereof that bind to human 4Ig-B7H3.

Patent Application: Multispecific Binding Constructs Against Checkpoint Molecules

The USPTO has published a new patent application (US20260085121A1) from Compass Therapeutics, LLC, detailing multispecific binding constructs against checkpoint molecules. The application focuses on compositions and methods for inhibiting tumor evasion by reducing immune checkpoint suppression, specifically blocking interactions between PD-1 and its ligand.

All-in-one Agonistic Antibodies Patent Application

The USPTO has published a patent application (US20260085113A1) filed by Hoffmann-La Roche Inc. on October 2, 2025. The application describes antigen binding molecules comprising biparatopic target-binding domains and cytokine receptor-binding domains designed to selectively activate cytokine receptors.